|
The device was used for treatment.The device was not returned for analysis as device was discarded, therefore, the clinical observation could not be confirmed.The investigation was focused on a review of product documentation.The device history records were reviewed to confirm that the device passed all applicable in-process and final inspections.However, following controls are in place to mitigate the reported product issue.Per procedure, destino steerable guiding sheath in-process and final inspection: side port assembly inspection,sample size: 100% visual inspection: verify correct color coded tubing is attached to side port tubing.Using a 10x microscope, inspect side port tube assembly for excessive glue at both joints.A bead of glue around the perimeter of the side port tube to hub joint is acceptable.Smeared glue on side port assembly is not acceptable.Check both the sheath hub to side port tube and stopcock to side port tube.Using a 10x microscope, check for loose and embedded fm and damages to hub, sheath, stopcock, and side tube.Check for fm in the stopcock manual tug test: using a metric ruler at a distance of 5mm to 10mm, check the integrity the bond gluing with firmness gently pulling on both joints: sheath hub to side port tube and stopcock to side port tube.Test sideport for occlusion by attaching a 10 cc syringe with plunger completely pulled out to the open stopcock valve.Test both outlets of the stopcock, one at a time.When testing one outlet, make sure the other is in off position push and pull the plunger of the syringe to confirm air flow through sideport and tube.If there is obstruction or blockage, it will be difficult to operate the plunger.No shafts should be accepted where blockage is felt.Per ifu: use the sideport, located at the handle, to inject contrast solution or fl ush the steerable sheath.The steerable sheath must be thoroughly flushed with either saline or heparinized saline and free of air prior to use to avoid air embolism to the patient.Never advance, torque, or withdraw sheath when resistance is met.Determine cause by fl uoroscopy and then take remedial action.Based on the investigation, a capa is not required as findings did not identify a design, labeling or manufacturing non-conformity.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|